miRagen Therapeutics is reshaping its strategy to focus on the development of MRG-229, a potential treatment for idiopathic pulmonary fibrosis (IPF). The company expects to share new efficacy and safety preclinical data on MRG-229 during the…
News
People with pulmonary fibrosis living in the Mercer and Bucks County regions of New Jersey and Pennsylvania now have access to a new pulmonary rehabilitation program. The program, launched by Capital Health in December, will be located at the Wellness Center at Capital Health Medical Center –…
A novel lab model replicates the main steps leading to progressive fibrosis, and can be used to assess the properties of therapeutic candidates, a study has found. The study, “Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small Molecule,” was published in the journal…
Men with idiopathic pulmonary fibrosis (IPF) have poorer lung function and a higher frequency of heart-related diseases (comorbidities) than women with IPF, according to a Swedish study. The data, which showed no differences between the sexes in terms of quality of life, suggest that additional research is required to…
The Canadian Registry for Pulmonary Fibrosis (CARE-PF) enrolled in its first 18 months more than 1,200 people with interstitial lung disease (ILD), with more than half having either idiopathic pulmonary fibrosis (IPF) or connective tissue disease-associated interstitial lung disease (CTD-ILD). Data collected through the CARE-PF registry could be useful…
Algernon Pharmaceuticals‘s NP-120 (ifenprodil) outperformed Merck‘s MK-7264 (gefapixant) in an animal model of acute cough, a preclinical study by a contract research organization (CRO) shows. NP-120 is Algernon’s repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), while MK-7264 is Merck’s lead candidate for the treatment…
Enrollment in the Phase 2 clinical trial of setanaxib (GKT831), an oral investigational treatment for idiopathic pulmonary fibrosis (IPF), will start in the coming weeks, Genkyotex announced in a progress report. Following approval by the U.S. Food and Drug Administration (FDA) in July, the study protocol now…
Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.
A joint research project between BioMed X and Boehringer Ingelheim has identified a new set of potential epigenetic targets for the treatment of two chronic lung diseases, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Epigenetics refers to DNA chemical modifications that can turn genes on or…
Treatment with Esbriet (pirfenidone) before and after cancer removal surgery reduces the risks of acute flares following the procedure in people with idiopathic pulmonary fibrosis (IPF) and lung cancer, a study finds. The findings were reported in “Perioperative pirfenidone treatment for lung cancer patients with…
